Hichi Pharmaceutical, a Subsidiary of Beilu Pharmaceutical: Iopromide API Approved for Market Launch

Recently, Hichi Pharmaceutical's Iopromide API has received the "Approval Notice for the Marketing Application of Chemical Raw Materials" from the National Medical Products Administration (NMPA). This approval marks another significant product following the approval of Iodixanol, Iohexol, and Iopamidol APIs.

The approval of Iopromide API will further diversify Hichi Pharmaceutical's API portfolio, driving steady growth in its API sales business and enhancing the company's market share in the contrast agent API sector.

At the same time, this will expand Beilu Pharmaceutical' integration of "API + Formulation" in the contrast agent field, creating favorable conditions for the company to continue strengthening its competitive advantage and market share in this sector.